Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

Also called NCT07146360

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 180 participants (enrolled count) (from the registry)
Sponsor
  • AO GENERIUM Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07146360
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07146360. Randomized; single masking; primary purpose treatment. Start 2014-05-25 (actual); primary completion 2017-11-21 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction
Condition
Myocardial Infarction (MI)
Intervention (Biological)
Revelise (GENERIUM, Russia)
Intervention (Biological)
Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany)
Lead sponsor
AO GENERIUM (class: industry)

Record details

Record id
cardio:ct-nct07146360
Content hash
e03126f55a4a3a82af5f60cb1214a71aae27948af903957f34c1700fde1b2ca9